InCarda Therapeutics

Palo Alto, CA

Deal Team:
Lou Lange

InCarda Therapeutics, Inc. is a biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions and diseases by the inhalation route. The advantage of inhalation is that it delivers “first pass” to cardiac tissue, presenting a bolus of a drug directly to affected regions of the heart. This permits rapid-onset, lower off-target tissue exposure of the drug, lower continued/prolonged exposure to cardiac tissue and more importantly can be patient administered.


AMV is a venture capital firm investing in
early-stage digital health, technology and
life sciences companies.

2595 E Bayshore Rd, Suite 240
Palo Alto, CA

© 2019 Asset Management Ventures
All Rights Reserved